-
1.发明授权公开(公告)号：US08124105B2
公开(公告)日：2012-02-28
申请号：US12489846
申请日：2009-06-23
申请人： Gary H. Cohen , Roselyn J. Eisenbert , John Charles Whitbeck , Lydia Aldaz-Carroll , Bernard Moss , Shlomo Lustig , Christiana Fogg
发明人： Gary H. Cohen , Roselyn J. Eisenbert , John Charles Whitbeck , Lydia Aldaz-Carroll , Bernard Moss , Shlomo Lustig , Christiana Fogg
IPC分类号： A61K39/00 , A61K39/12 , A61K39/295 , A61K39/275 , C07H21/02
CPC分类号： C07K14/005 , A61K39/12 , A61K39/285 , A61K2039/505 , A61K2039/53 , C07K16/081 , C07K2317/76 , C12N2710/24122 , C12N2710/24134
摘要： The invention is directed to a poxvirus vaccine comprising a soluble truncated poxvirus envelope protein. The invention is also directed to a vaccine comprising a nucleic acid encoding such proteins. Also included is an antibody which specifically binds to the proteins and nucleic acid encoding the same, as well as methods of preventing and treating a poxvirus infection using the afore-mentioned vaccine, antibody, protein, and nucleic acid encoding them.
摘要翻译： 本发明涉及包含可溶性截短痘病毒包膜蛋白的痘病毒疫苗。 本发明还涉及包含编码这种蛋白质的核酸的疫苗。 还包括特异性结合蛋白质的抗体及其编码的核酸，以及使用上述疫苗，抗体，蛋白质和编码它们的核酸来预防和治疗痘病毒感染的方法。
-
2.发明申请公开(公告)号：US20100021484A1
公开(公告)日：2010-01-28
申请号：US12489846
申请日：2009-06-23
申请人： Gary H. Cohen , Roselyn J. Eisenbert , John Charles Whitbeck , Lydia Aldaz-Carroll , Bernard Moss , Shlomo Lustig , Christiana Fogg
发明人： Gary H. Cohen , Roselyn J. Eisenbert , John Charles Whitbeck , Lydia Aldaz-Carroll , Bernard Moss , Shlomo Lustig , Christiana Fogg
CPC分类号： C07K14/005 , A61K39/12 , A61K39/285 , A61K2039/505 , A61K2039/53 , C07K16/081 , C07K2317/76 , C12N2710/24122 , C12N2710/24134
摘要： The invention is directed to a poxvirus vaccine comprising a soluble truncated poxvirus envelope protein. The invention is also directed to a vaccine comprising a nucleic acid encoding such proteins. Also included is an antibody which specifically binds to the proteins and nucleic acid encoding the same, as well as methods of preventing and treating a poxvirus infection using the afore-mentioned vaccine, antibody, protein, and nucleic acid encoding them.
摘要翻译： 本发明涉及包含可溶性截短痘病毒包膜蛋白的痘病毒疫苗。 本发明还涉及包含编码这种蛋白质的核酸的疫苗。 还包括特异性结合蛋白质的抗体及其编码的核酸，以及使用上述疫苗，抗体，蛋白质和编码它们的核酸来预防和治疗痘病毒感染的方法。
-
3.发明授权公开(公告)号：US07560116B2
公开(公告)日：2009-07-14
申请号：US11010979
申请日：2004-12-13
申请人： Gary H. Cohen , Roselyn J. Eisenberg , John Charles Whitbeck , Lydia Aldaz-Carroll , Bernard Moss , Shlomo Lustig , Christiana Fogg
发明人： Gary H. Cohen , Roselyn J. Eisenberg , John Charles Whitbeck , Lydia Aldaz-Carroll , Bernard Moss , Shlomo Lustig , Christiana Fogg
IPC分类号： A61K39/38 , A61K39/12 , A61K39/295 , A61K39/285 , C07K17/00 , A61K39/187
CPC分类号： C07K14/005 , A61K39/12 , A61K39/285 , A61K2039/505 , A61K2039/53 , C07K16/081 , C07K2317/76 , C12N2710/24122 , C12N2710/24134
摘要： The invention is directed to a poxvirus vaccine comprising a soluble truncated poxvirus envelope protein. The invention is also directed to a vaccine comprising a nucleic acid encoding such proteins. Also included is an antibody which specifically binds to the proteins and nucleic acid encoding the same, as well as methods of preventing and treating a poxvirus infection using the afore-mentioned vaccine, antibody, protein, and nucleic acid encoding them.
摘要翻译： 本发明涉及包含可溶性截短痘病毒包膜蛋白的痘病毒疫苗。 本发明还涉及包含编码这种蛋白质的核酸的疫苗。 还包括特异性结合蛋白质的抗体及其编码的核酸，以及使用上述疫苗，抗体，蛋白质和编码它们的核酸来预防和治疗痘病毒感染的方法。
-
公开(公告)号：US20060062800A1
公开(公告)日：2006-03-23
申请号：US11010979
申请日：2004-12-13
申请人： Gary Cohen , Roselyn Eisenberg , John Whitbeck , Lydia Aldaz-Carroll , Bernard Moss , Shlomo Lustig , Christiana Fogg
发明人： Gary Cohen , Roselyn Eisenberg , John Whitbeck , Lydia Aldaz-Carroll , Bernard Moss , Shlomo Lustig , Christiana Fogg
IPC分类号： C12Q1/70 , A61K39/12 , C07K14/065
CPC分类号： C07K14/005 , A61K39/12 , A61K39/285 , A61K2039/505 , A61K2039/53 , C07K16/081 , C07K2317/76 , C12N2710/24122 , C12N2710/24134
摘要： The invention is directed to a poxvirus vaccine comprising a soluble truncated poxvirus envelope protein. The invention is also directed to a vaccine comprising a nucleic acid encoding such proteins. Also included is an antibody which specifically binds to the proteins and nucleic acid encoding the same, as well as methods of preventing and treating a poxvirus infection using the afore-mentioned vaccine, antibody, protein, and nucleic acid encoding them.
-
5.发明授权Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites 有权含有重组插入位点的重组修饰牛痘安卡拉（MVA）痘苗病毒公开(公告)号：US09133480B2
公开(公告)日：2015-09-15
申请号：US13502205
申请日：2010-10-15
申请人： Bernard Moss , Linda S. Wyatt , Patricia L. Earl
发明人： Bernard Moss , Linda S. Wyatt , Patricia L. Earl
IPC分类号： C12N15/86 , C12N15/863 , C12N7/00 , C07K14/005 , A61K39/285 , A61K39/00
CPC分类号： C12N7/00 , A61K39/285 , A61K2039/5256 , C07K14/005 , C12N15/86 , C12N15/8636 , C12N2710/24121 , C12N2710/24133 , C12N2710/24143 , C12N2710/24152 , C12N2740/16122 , C12N2740/16222
摘要： The present invention relates to recombinant modified vaccinia Ankara (MVA) virus containing restructured sites useful for the integration of heterologous nucleic acid sequences into an intergenic region (IGR) of the virus genome, where the IGR is located between two adjacent, essential open reading frames (ORFs) of the vaccinia virus genome, wherein the adjacent essential ORFs are non-adjacent in a parental MVA virus used to construct the recombinant MVA virus, and to related nucleic acid constructs useful for inserting heterologous DNA into the genome of a vaccinia virus, and further to the use of the disclosed viruses as a medicine or vaccine.
摘要翻译： 本发明涉及含有用于将异源核酸序列整合到病毒基因组的基因间区域（IGR）中的重组位点的重组修饰牛痘安卡拉（MVA）病毒，其中IGR位于两个相邻的基本开放阅读框之间 （ORF），其中相邻的必需ORF在用于构建重组MVA病毒的亲代MVA病毒中不相邻，以及可用于将异源DNA插入痘苗病毒基因组中的相关核酸构建体， 并且进一步使用所公开的病毒作为药物或疫苗。
-
公开(公告)号：US08404818B2
公开(公告)日：2013-03-26
申请号：US13038613
申请日：2011-03-02
CPC分类号： C07K16/081 , A61K39/00 , A61K2039/505 , A61K2039/545 , C07K14/005 , C07K2317/21 , C07K2317/24 , C07K2317/51 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N2710/24122 , G01N33/56983 , G01N2333/07
摘要： The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
摘要翻译： 本发明涉及结合或中和正痘病毒的单克隆抗体。 本发明提供了这样的抗体，这种抗体保留B5或A33结合能力的片段，完全人抗体保留B5或A33结合能力，以及包含这些抗体的药物组合物。 本发明还提供了编码本发明的抗体的分离的核酸和用其转化的宿主细胞。 另外，本发明提供了使用本发明的抗体和核酸的预防，治疗和诊断方法。
-
公开(公告)号：US20110159036A1
公开(公告)日：2011-06-30
申请号：US11975643
申请日：2007-10-19
申请人： Bernard Moss , Patricia L. Earl , Linda Wyatt , Leigh Anne Eller , Thomas C. VanCott , Matthew Edward Harris
发明人： Bernard Moss , Patricia L. Earl , Linda Wyatt , Leigh Anne Eller , Thomas C. VanCott , Matthew Edward Harris
CPC分类号： C12N15/86 , A61K2039/5256 , A61K2039/53 , A61K2039/57 , C07K14/005 , C12N2710/24143 , C12N2740/16122 , C12N2740/16222 , C12N2830/00 , C12N2830/15 , C12N2830/60
摘要： The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.
摘要翻译： 本发明提供了修饰的病毒安卡拉（MVA），一种表达人免疫缺陷病毒（HIV）env，gag和pol基因的痘苗病毒复制缺陷型菌株。
-
公开(公告)号：US07494813B2
公开(公告)日：2009-02-24
申请号：US10959392
申请日：2004-10-05
申请人： Bernard Moss , Arban Domi
发明人： Bernard Moss , Arban Domi
CPC分类号： C12N15/86 , C12N15/70 , C12N2710/14143 , C12N2710/24043 , C12N2710/24143 , C12N2770/24143 , C12N2800/204
摘要： The invention relates to a VAC-BAC shuttle vector system for creation of recombinant poxviruses from DNA cloned in a bacterial artificial chromosome.
摘要翻译： 本发明涉及一种用于从克隆在细菌人造染色体中的DNA产生重组痘病毒的VAC-BAC穿梭载体系统。
-
9.发明申请Recombinant Mva Viruses Expressing Clade A/G, Clade B, and Clade C Modified Hiv Env Gag and Pol Genes 有权表达进化枝A / G，克隆B和克隆C修饰的Hiv Env Gag和Pol基因的重组Mva病毒公开(公告)号：US20080193483A1
公开(公告)日：2008-08-14
申请号：US11574285
申请日：2005-08-29
申请人： Bernard Moss , Linda Wyatt , Harriet L. Robinson
发明人： Bernard Moss , Linda Wyatt , Harriet L. Robinson
IPC分类号： A61K39/285 , A61K48/00 , C12N7/01
CPC分类号： C12N15/86 , A61K2039/5256 , A61K2039/53 , A61K2039/57 , C07K14/005 , C12N2710/24143 , C12N2740/16023 , C12N2740/16122 , C12N2740/16134 , C12N2740/16222 , C12N2740/16234 , C12N2830/00 , C12N2830/15 , C12N2830/60
摘要： The invention provides modified vaccinia Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.
摘要翻译： 本发明提供了修饰的痘苗Ankara（MVA），一种表达人免疫缺陷病毒（HIV）env，gag和pol基因的痘苗病毒复制缺陷型菌株。
-
公开(公告)号：US07208313B2
公开(公告)日：2007-04-24
申请号：US09991721
申请日：2001-11-13
IPC分类号： C12N15/863 , A61K48/00
CPC分类号： C12N15/86 , A61K48/00 , A61K2039/5156 , C12N2710/24122 , C12N2710/24132 , C12N2710/24143
摘要： A composition of matter comprising a vaccinia virus expression vector with a negative thymidine kinase phenotype and a negative vaccinia virus growth factor phenotype.
-
-
-
-
-
-
-
-
-
搜索结果
54 条记录 (耗时 0.05 秒)
